Copyright: ©Author(s) 2026.
World J Methodol. Jun 20, 2026; 16(2): 115754
Published online Jun 20, 2026. doi: 10.5662/wjm.v16.i2.115754
Published online Jun 20, 2026. doi: 10.5662/wjm.v16.i2.115754
Table 2 Investigations, clinical course and outcomes in included children, n (%)/mean ± SD
| Characteristics | All patients (n = 200) | Bacterial (n = 39) | Viral (n = 15) | Atypical (n = 7) | P value |
| Complete blood count | |||||
| Total leucocyte count (cumm) | 15417.4 ± 5551.1 | 17417.2 ± 3254.8 | 14226.4 ± 2119.6 | 13112.4 ± 1792.2 | 0.39 |
| Hemoglobin (g/dL) | 10.6 ± 1.8 | 10.9 ± 1.4 | 11.0 ± 1.6 | 11.1 ± 1.2 | 0.76 |
| Neutrophil (%) | 84 ± 6.4 | 84 ± 6.1 | 72 ± 7.3 | 73 ± 7.1 | 0.59 |
| Lymphocyte (%) | 31 ± 5.2 | 28 ± 5.4 | 33 ± 6.1 | 32 ± 4.8 | 0.84 |
| Platelet count (lakhs/cumm) | 2.4 ± 0.9 | 2.4 ± 1.5 | 2.7 ± 1.2 | 2.6 ± 1.2 | 0.91 |
| Liver function tests | |||||
| Total bilirubin (mg/dL) | 0.9 ± 0.2 | 1.1 ± 0.2 | 1.4 ± 0.3 | 0.8 ± 0.1 | 0.65 |
| Total protein (g/L) | 7.7 ± 0.9 | 7.7 ± 0.8 | 7.6 ± 1.1 | 7.6 ± 0.9 | 0.77 |
| Aspartate transaminase (U/L) | 41 ± 8.4 | 36 ± 7.9 | 45 ± 8.1 | 44 ± 7.7 | 0.44 |
| Alanine transaminase (U/L) | 37 ± 6.5 | 36 ± 6.7 | 39 ± 6.1 | 38 ± 6.6 | 0.82 |
| Renal function tests | |||||
| Urea (mg/dL) | 29 ± 8.4 | 29 ± 8.1 | 27 ± 9.1 | 28 ± 8.8 | 0.69 |
| Creatinine (mg/dL) | 0.8 ± 0.2 | 0.8 ± 0.2 | 0.8 ± 0.2 | 0.8 ± 0.2 | 0.93 |
| Inflammatory markers | |||||
| Erythrocyte sedimentation rate (mm/hour) | 28 ± 12 | 23 ± 11 | 32 ± 8 | 26 ± 10 | 0.46 |
| C-reactive protein (mg/L) | 22 ± 9 | 42 ± 6 | 28 ± 7 | 20 ± 5 | 0.37 |
| Chest X ray findings | |||||
| Heterogenous opacities/infiltrates | 106 (53) | 14 (35.9) | 13 (86.7) | 6 (85.7) | 0.07 |
| Consolidation | 73 (36.5) | 25 (64.1) | 2 (13.3) | 1 (14.3) | P < 0.01 |
| Duration of antibiotics use | |||||
| 5-10 days | 142 (71) | 26 (66.7) | 15 (100) | 7 (100) | - |
| > 10 days | 58 (29) | 13 (33.3) | 0 (0) | 0 (0) | 0.002 |
| Type of respiratory support | |||||
| Nasal cannula/face mask | 200 (100) | 39 (100) | 15 (100) | 7 (100) | - |
| Continuous positive airway pressure | 43 (21.5) | 7 (17.9) | 3 (13.3) | 1 (14.3) | 0.63 |
| Heated humidified high flow nasal cannula | 40 (20) | 15 (38.5) | 6 (40) | 3 (42.9) | 0.38 |
| Mechanical ventilation | 36 (18) | 6 (15.4) | 4 (26.6) | 1 (14.3) | 0.71 |
| Pneumonia severity types | |||||
| Moderate | 115 (57.5) | 19 (48.7) | 9 (60) | 5 (71.4) | 0.33 |
| Severe | 49 (24.5) | 13 (33.3) | 4 (26.7) | 1 (14.3) | 0.27 |
| Very severe | 36 (18) | 7 (18) | 2 (13.3) | 1 (14.3) | 0.48 |
| Outcomes | |||||
| Discharged | 182 (91) | 33 (84.6) | 13 (86.7) | 7 (100) | 0.51 |
| Died | 18 (9) | 6 (15.4) | 2 (13.3) | 0 | 0.42 |
- Citation: Kanungo SK, Hembram G, Sahu PK, Das RR. Serum procalcitonin as a predictor of severity of pneumonia in under-five children: A prospective observational study. World J Methodol 2026; 16(2): 115754
- URL: https://www.wjgnet.com/2222-0682/full/v16/i2/115754.htm
- DOI: https://dx.doi.org/10.5662/wjm.v16.i2.115754